Research

AGILE (Advanced Genomics Institute & Laboratory Medicine) is a dedicated research hub committed to transforming genomic discoveries into diagnostic and therapeutic realities. Our research spans:

Genotype–Phenotype Mapping, population genetics, and mutation profiling
Disease Understanding: pathology, comorbidity, prevalence, prognostic markers
Optimizing Therapies: personalized dosing, efficacy, resistance profiles
Technique & Cost Innovation: improving laboratory workflows and diagnostics
Technology Validation: from kits to consumables across diverse applications

Mutation Profiling in Indian Thalassemia Cases – Identifying unique mutation patterns in regional populations.
Chromosomal Studies in High‑Risk Pregnancies – (North India cohort analysis).
Stem Cell Cytogenetics – Mapping chromosomal anomalies in cultured stem cell lines.
Array CGH in Neonatal Anomalies – Detection of genomic imbalances in newborns with congenital anomalies. (Collaborator: Dr. Raunak Jahan, BSMMU, Bangladesh)
Lab‑on‑Chip POC Device for Pre‑diabetic Hyperinsulinemia – Integrating metabolic & genomic markers into point‑of‑care testing. (Collaborator: Dr. Anu Joseph, Aster MIMS)

Direct, extraction‑free SARS‑CoV‑2 RNA detection via saliva or swab.
CCND1 gene copy number in oral squamous cell carcinoma prognosis (with SMS Medical College, Jaipur).
Application of microarray in detecting prenatal chromosome abnormalities.
Balanced translocations in recurrent pregnancy loss and IVF failures.
Prenatal FISH screening for chromosomal irregularities in high‑risk pregnancies.

Key Research Areas

We investigate how genetic variation shapes health anddisease across populations. ‍
‍

Core goals include:
‍

Correlating genotypes with clinical phenotypes
Profiling mutations across diverse populations
Enabling predictive screening and early diagnosis

Outcome: Stronger genetic risk assessment andtailored carrier screening for inherited disorders

Our teams delve into the genetic architecture of disease—its causes, modifiers, and clinical expressions.
‍

Focus areas:
‍

Causality and progression of complex diseases
Prevalence studies and comorbidity insights
Prognostic markers and genomic biomarkers
‍

Outcome: Deeper insights for accurate diagnosis and better patient management.

We explore how genes influence drug response, treatment resistance, and dosage efficacy

Research themes:
‍

Pharmacogenomics and personalized treatment planning
Genetic determinants of drug resistance and ADRs
Stratification of patients for targeted therapies
‍

Outcome: Informed therapy decisions and optimized patient care.

Innovation in diagnostics starts in the lab. We continuously refine and validate our methodologies.
‍

Areas of development:
‍

Improving turnaround times and test reliability
Simplifying workflows in molecular and cytogenetic diagnostics
Making diagnostics more cost-effective without compromising quality
‍

Outcome: Scalable, affordable, and high-impact testing solutions.

We bridge the gap between emerging genomic technologies and their real-world application.

‍

Research includes:
‍

Clinical validation of NGS, cfDNA, and digital PCR platforms
Integration of AI tools for variant classification
Application studies in oncology, rare diseases, and reproductive genetics
‍

Outcome: Faster adoption of clinically relevant, next-generation diagnostic platforms.

We evaluate the building blocks of diagnostics—kits, reagents, media, and instruments—to ensure they meet clinical demands.
‍

Evaluation criteria:
‍

Sensitivity, specificity, and stability across sample types
Compatibility with high-throughput and decentralized workflows
Quality assurance for consistent performance
‍

Outcome: High-confidence results from validated, reliable laboratory tools.

Research

Key Research Areas

Corporate

Test & Services